[1] Greenberg PL, Attar E, Bennett JM, et al.Myelodysplastic syndromes: clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2013,11(7):838-874.
[2] Pang WW, Pluvinage JV, Price EA, et al.Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes[J]. Proc Natl Acad Sci U S A,2013,110(8):3011-3016.
[3] Ma X, Does M, Raza A, et al.Myelodysplastic syndromes: incidence and survival in the United States[J]. Cancer,2007,109(8):1536-1542.
[4] Kantarjian H, Giles F, List A, et al.The incidence and impact of thrombocytopenia in myelodysplastic syndromes[J]. Cancer,2007,109(9):1705-1714.
[5] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361.
[6] Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes[J]. Am J Hematol,2008,83(10):765-770.
[7] Sekeres MA, Schoonen WM, Kantarjian H, et al.Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys[J]. J Natl Cancer Inst,2008,100(21):1542-1551.
[8] Goodnough LT, DiPersio JF. Issues in the management of cancer-related thrombocytopenia[J]. Oncology (Williston Park),2002,16(11):1558-1567,1570,1572-1574.
[9] Yamada M, Komatsu N, Kirito K, et al.Thrombopoietin supports in vitro erythroid differentiation via its specific receptor c-Mpl in a human leukemia cell line[J]. Cell Growth Differ,1998,9(6):487-496.
[10] Kuter DJ.New thrombopoietic growth factors[J]. Clin Lymphoma Myeloma,2009,9(Suppl 3):S347-S356.
[11] Kuter DJ.Romiplostim[J]. Cancer Treat Res,2011,157:267-288.
[12] Broudy VC, Lin NL.AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl[J]. Cytokine,2004,25(2):52-60.
[13] Erickson-Miller C, Tian S, Hopson C, et al.Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115[J]. Transfusion,2005,45S(3):43A.
[14] Erickson-Miller CL, Delorme E, Tian SS, et al.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells,2009, 27(2):424-430.
[15] Haselboeck J, Pabinger I, Ay C, et al.Platelet activation and function during eltrombopag treatment in immune thrombocytopenia[J]. Ann Hematol,2012,91(1):109-113.
[16] Bussel JB, Kuter DJ, Pullarkat V, et al.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J]. Blood,2009,113(10):2161-2171.
[17] Kantarjian H, Fenaux P, Sekeres MA, et al.Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia[J]. J Clin Oncol,2010,28(3):437-444.
[18] Sekeres MA, Kantarjian H, Fenaux P, et al.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes[J]. Cancer,2011,117(5):992-1000.
[19] Giagounidis A, Mufti GJ, Fenaux P, et al.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia[J]. Cancer,2014,120(12):1838-1846.
[20] Santini V.Novel therapeutic strategies: hypomethylating agents and beyond[J]. Hematology Am Soc Hematol Educ Program,2012,2012:65-73.
[21] Santini V, Fenaux P, Mufti GJ, et al.Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*[J]. Eur J Haematol,2010,85(2):130-138.
[22] Kantarjian HM, Giles FJ, Greenberg PL, et al.Phase 2 study of romiplostim in patients with low- or interme-diate-risk myelodysplastic syndrome receiving azacitidine therapy[J]. Blood,2010,116(17):3163-3170.
[23] Greenberg PL, Garcia-Manero G, Moore M, et al.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine[J]. Leuk Lymphoma,2013,54(2):321-328.
[24] Jädersten M, Hellström-Lindberg E.Myelodysplastic syndromes: biology and treatment[J]. J Intern Med,2009,265(3):307-328.
[25] Mohamedali A, Mufti GJ.Van-den Berghe's 5q- syndrome in 2008[J]. Br J Haematol,2009,144(2):157-168.
[26] List A, Dewald G, Bennett J, et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med,2006,355(14):1456-1465.
[27] Wang ES, Lyons RM, Larson RA, et al.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide[J]. J Hematol Oncol,2012, 5:71.
[28] Prica A, Sholzberg M, Buckstein R.Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials[J]. Br J Haematol,2014,167(5):626-638.
[29] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328.
[30] Tamari R, Schinke C, Bhagat T, et al.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone[J]. Leuk Lymphoma,2014,55(12):2901-2906.
[31] Sellers T, Hart T, Semanik M, et al.Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs[J]. Blood,2004,104(111):568A.
[32] Jenkins JM, Williams D, Deng Y, et al.Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist[J]. Blood,2007,109(11):4739-4741.
[33] Will B, Kawahara M, Luciano JP, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908.
[34] Svensson T, Chowdhury O, Garelius H, et al.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine[J]. Eur J Haematol,2014,93(5):439-445.
[35] Dickinson M, Herbert K, Sardjono C, et al.High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML[J]. Leuk Res,2013,371:S147.
[36] Oliva EN, Santini V, Zini G, et al.Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial[J]. Leuk Res,2013,371:S162.
[37] Oliva EN, Santini V, Zini G, et al.Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial(EQoL-MDS)[J]. Blood,2012,120(21).
[38] Kalina U, Hofmann WK, Koschmieder S, et al.Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes[J]. Exp Hematol,2000,28(10):1158-1163.
[39] Luo SS, Ogata K, Yokose N, et al.Effect of thrombo-poietin on proliferation of blasts from patients with myelodysplastic syndromes[J]. Stem Cells,2000,18(2):112-119.
[40] Platzbecker U, Wong RS, Verma A, et al.Safety and tole-rability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial[J]. Lancet Haematol,2015,2(10):e417-e426.
[41] Will B, Kawahara M, Luciano J P, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908.
[42] Kalota A, Gewirtz AM.A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells[J]. Blood,2010,115(1):89-93.
[43] Roth M, Will B, Simkin G, et al.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation[J]. Blood,2012,120(2):386-394.
[44] Erickson-Miller CL, Kirchner J, Aivado M, et al.Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag[J]. Leuk Res,2010,34(9):1224-1231.
[45] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328.
[46] Sugita M, Kalota A, Gewirtz AM, et al.Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression[J]. Leukemia,2013,27(5):1207-1210.
